Study Details
Full Title
A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure with Preserved Ejection Fraction (HFpEF)
Principal Investigator
Mustafa
Bashir
Protocol Number
PRO00120375
NCT ID
NA
Phase
N/A
Enrollment Status
Open to Enrollment